Generally, “hot” tumors are more sensitive to immune checkpoint therapy.[30] Currently, blocking immune checkpoints is one of the most promising immunotherapeutic strategies for cancer, which aim to reverse intra-tumoral T cell dysfunction and reactivate antitumor immunity.[31] In PDAC, the expression of PD-L1 was proved to negatively correlated with the overall survival of patients. This evidence concerns the gene CD274 and cancer.